Chronic Lymphocytic Leukemia Coverage from Every Angle
Advertisement
Advertisement

Recent News

Use of Ibrutinib During COVID-19–Induced Respiratory Failure in CLL: Case Study
Novel Mutation and CLL Resistance to BTK and SYK Inhibition: Case Study
Exploring Rapid Dose Escalation of Venetoclax in Patients With CLL
Personalizing Management of CLL: From the Advanced Practitioner Perspective
Can LCK Deletion Result in Acceleration of CLL?
Comparing Front-Line Treatments in CLL: Focus on Acalabrutinib
Adding Zanubrutinib to Obinutuzumab in CLL
Early Use of Lenalidomide With Pneumococcal Vaccine for High-Risk CLL
Genetic Landscape of CLL With IGH Translocations
SOHO 2020: Link Between WNT3 and LEF1 Expression Levels and Survival in CLL?
SOHO 2020: Interim Analysis of Real-World Registry of Elderly Patients With CLL
Managing CLL in the Era of COVID-19: Guidance From Global Experts
SOHO 2020: Debulking Regimens Prior to Venetoclax Therapy for CLL
SOHO 2020: Chemotherapy-Free Combination Therapy for CLL Under Study in Phase III Trial
Bendamustine Plus Rituximab in Older Patients With CLL: Swedish Real-World Study
Chemoimmunotherapy Regimen Under Study in Younger Patients With CLL
Case Report of Breast Involvement in a Male Patient With CLL
High-Risk CLL: Hematopoietic Stem Cell Transplantation Followed by Immune Intervention
Study Shows Benefit of Novel Agents for CLL With 17p Deletion
CLL and COVID-19: Large Italian Survey on Changes in Management
Case Report Features Potential Link Between JAK2 Inhibition and CLL
CLL and COVID-19: Treatment Lessons Learned
CLL and COVID-19: Continuity of Care in Italian Tertiary Hospital
FDA Clearance Granted for Assay for Monitoring Minimal Residual Disease in CLL
Dual PI3Kδ/CK1ε Inhibition on CLL T Cells
Predictors of Outcome in Patients with CLL and COVID-19
Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?
CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?
Zanubrutinib for Resistant CLL and Small Lymphocytic Lymphoma
Two Decades of Data Confirm Poor Prognosis With Richter Transformation in CLL
EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL
EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?
Real-World Study Finds VHA Adopts Novel Agents in CLL Treatment
AACR II: Linking HPV Infection to Skin Cancer in Patients With CLL
EHA25 Virtual: First-Line Ibrutinib/Venetoclax Combination in CLL
EHA25 Virtual: Trial Update on Ibrutinib Plus Umbralisib in Resistant CLL
ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
EHA25 Virtual: Long-Term Results With Acalabrutinib in Treatment-Naive CLL
ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL
EHA25 Virtual: VENICE-I Findings With Venetoclax in Resistant CLL
EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL
ASCO20: Does Early Discontinuation of Venetoclax Affect Outcomes in CLL?
ASCO20: Cirmtuzumab Plus Ibrutinib in Relapsed or Refractory CLL
ASCO20: Final Results From ASCEND Trial of Acalabrutinib in Resistant CLL
ASCO20: Intermittent Scheduling of PI3Kδ Inhibitor in CLL


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.